

# **ANNUAL REPORT 2019**

Broadview Ventures, Inc. | 265 Franklin Street, Suite 1902 | Boston MA, 02110 | broadviewventures.org | 617.459.4686

### 2019 PORTFOLIO MOMENTUM

- The Broadview pipeline remains robust with more than 500 investment opportunities considered in 2019
- Our portfolio companies raised \$122M in co-investments, follow-on financings, and grants
- This year, across our portfolio, our co-investors included ARCH
  Venture Partners, Longitude Capital, Longevity Fund, Novartis Venture
  Fund, New Leaf Ventures, Innogest
  Capital, Abiomed, and S3 Ventures
- The technologies of Broadview's portfolio companies have touched the lives of more than 100,000 patients to date

#### **NEW INVESTMENTS**

- Alleviant Medical—atrial shunt for the treatment of heart failure
- **Renovacor**—gene therapy for a rare, familial form of dilated cardiomyopathy
- **CroiValve**—percutaneously implanted device to restore tricuspid valve function

# VENTURES


Last year, the Leducq Trust launched Longview Ventures, a \$100M fund dedicated to making follow-on investments in select Broadview portfolio companies. Longview will focus on clinical-stage companies to complement Broadview's continued dedication to early-stage financings. This year, we made two Longview investments:

- FineHeart—fully implantable, miniaturized circulatory support device for heart failure
- Aria CV—device for pulmonary artery hypertension

### TALENT


**Hewmun Lau** joined the Broadview investment team as a Principal, with 10 years of life science experience across business development, commercial operations, consulting and R&D. Most recently, she was Director of Corporate Development at Merrimack Pharmaceuticals. Hewmun holds a BS from Brandeis University, an MS from the Harvard-MIT Program in Health Sciences in Technology, and an MBA from MIT's Sloan School of Management.

**Daniel Gottlieb** joined the Broadview investment team as an Associate Director, with 20 years of medical device and biotechnology experience in corporate and business development, corporate venture capital, marketing and strategy. Most recently, he was Vice President, Corporate Development at Proteon Therapeutics. Daniel holds a BA from the University of Pennsylvania and an MBA from the Tuck School of Business at Dartmouth College.



BROADVIEW'S INVESTMENTS ARE LEVERAGED 12X BY CO-AND

#### BROADVIEW INVESTMENTS BY INDICATION



# **INVESTMENTS THROUGH 2019**

Company	Technology/Therapy	Founders/Management
2019		
Alleviant Medical	atrial shunt for the treatment of heart failure	Jacob Kriegel, Adam Berman
Renovacor	gene therapy for a rare, familial form of dilated cardiomyopathy	Maggie Cook, Arthur Feldman
CroíValve	percutaneously implanted device to restore tricuspid valve function	Lucy O'Keeffe, Martin Quinn
2018		
AtaCor Medical	leadless extravascular pacing system for bradycardia	Rick Sanghera, Sean McGeehan, Alan Marcovecchio
Kantum Pharma	small molecule therapeutic for cardiac surgery-associated AKI	Sylvie Breton, Glenn Batchelder
2017		
Nido	device for epicardial ablation of ventricular tachycardia	Pedro del Nido, Nikolay Vasilyev, Thomas Marchand
Mellitus	novel biomarker for the screening and diagnosis of gestational diabetes	Jose Halperin, Michael Chorev
Adient Vectorious	bioresorbable IVC filter for prevention of pulmonary embolism miniature wirelessly-powered implantable left atrial pressure sensor	Mitch Eggers, Joseph Steele Oren Goldshtein, Eyal Orion
EP Sciences	novel defibrillation waveform to reduce pain associated with ICD therapies	-
	novel denomination wavelorm to reduce pair associated with red therapies	Kon Beiger, noward Levin
2016	fully implantable ministurized singulatory support device for HE	Arnoud Maccorroll Stanhana Garrigua Joan Lus Paulnais
FineHeart Gila Therapeutics	fully implantable, miniaturized circulatory support device for HF PYY agonist for management and treatment of obesity	Arnaud Mascarell, Stephane Garrigue, Jean-Luc Boulnois Tom Vasicek
Aeromics	novel drug candidate for stroke-related cerebral edema	Tom Zindrick, Trevor Thompson, Marc Pelletier
2015		,
Pulmokine*	small molecule for pulmonary artery hypertension	Larry Zisman, Shreefal Mehta
Lyra Therapeutics	bioresorbable stent for multiple indications	Bob Langer, George Whitesides, Maria Palasis
Epirium	mitochondrial biogenesis platform technology	George Schreiner, Sundeep Dugar, Russell Cox
2014		
ZZ Biotech	peptide therapeutic for stroke	Berislav Zlokovic, Kent Pryor, Joseph Romano
Ischemia Care	gene-based diagnostic for stroke	Jeff June
Acesion Pharma	small molecule therapeutic for AF	Ulrik Sørensen, Morten Grunnet, Frans Wuite
Aria CV	device for pulmonary hypertension	John Scandurra, Karl Vollmers, Dan Gladney
2013		
Zumbro Discovery	peptide therapeutic for treatment of resistant hypertension	John Burnett, Horng Chen
BioKier	small molecule anti-diabetic treatment	George Szewczyk, Roger Nolan
Remedy* GI Windows*	small molecule for the treatment of central nervous system edema	Sven Jacobson Chris Thomason Mamin Busu
	non-surgical approach to gastric bypass	Chris Thompson, Marvin Ryou
2012	automal summer the same har successing successing the in CADC	Fuel Origin
VGS InfoBionic	external support for saphenous vein grafts in CABG cloud-based remote arrhythmia monitoring	Eyal Orion Jeremy Ruskin, Stuart Long
Herantis	VEG-F based gene therapy for lymphedema	Pekka Simula
Declmmune	MAb for treatment of post MI and I/R injury	Christopher Mirabelli, Walter Newman
2011	, , , , ,	· · ·
Cardialen	implantable cardioversion for the treatment of AF	Igor Efimov, Jeff Peters
NuPulse	counterpulsation device for the treatment of HF	Valluvan Jeevanandam, Douglas Altschuler
Aggamin	novel preeclampsia treatment	Ravi Thadhani, Paul Kussie, Ananth Kamuranchi
Provasculon*	peptide therapeutics for treatment of MI and I/R injury	Rich Lee, Roger Kitterman
Apama*	novel ablation system for treatment of AF	Amr Salahieh
2010		
Allosteros	CaMKII inhibitors for HF and AF	Howard Schulman, Mark Anderson
Intravascular Imaging		Farouc Jaffer, Vasilis Ntziachristos
Capricor*	allogeneic stem cell therapy after MI	Eduardo and Linda Marbán
CellAegis	remote ischemic conditioning for MI	Andrew Redington, Chris Calderone, Rocky Ganske
CardiAQ Valve*	transcatheter mitral valve	Brent Ratz, Arshad Quadri, Rob Michiels
VentriNova miRagen*	gene therapy for regeneration of cardiac tissue microRNAs for cardiovascular and oncology indications	Hina Chaudhry Bruce Booth, Mike Bristow, Eric Olson
minagen	microstradio caralovascular and oncology indications	Brace Booth, white Bristow, Life Ofson
* Exited		

**OUR MISSION** is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular and neurovascular diseases through targeted investments.



# **BROADVIEW TEAM**

### MANAGEMENT

Christopher Colecchi Managing Director

Maria Berkman, MD Adam Cohen Christopher de Souza, PhD Daniel Gottlieb Benjamin Kreitman Hewmun Lau David Milan, MD Nichole Neal Tom Needham ADVISORS

Annabel Chen-Tournoux, MD Teo Dagi, MD Marc Semigran, MD

# STRATEGIC ADVISORY BOARD

Eugene Braunwald, MD Kim Fox, MD Thomas Hughes, PhD Constantino Iadecola, MD Jerry Karabelas, PhD Martín Landaluce Joseph Loscalzo, MD, PhD Eric Rose, MD David Tancredi, MD, PhD



# LONGVIEW VENTURES INVESTMENT ADVISORY COMMITTEE

# EXTERNAL MEMBERS Terry McGuire Chris Mirabelli, PhD Eric Rose, MD

LEDUCQ MEMBERS Martín Landaluce David Tancredi, MD, PhD